What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
1. FDA's Prasad resigns amid pressure and controversy over approvals. 2. Capricor's BLA for Deramiocel received a Complete Response Letter. 3. FDA cites insufficient evidence for Deramiocel, requests additional data. 4. Cell therapy sector struggles with regulatory uncertainty post-Prasad's departure. 5. CAPR stock rose 16.2% despite regulatory challenges.